Sökning: onr:"swepub:oai:DiVA.org:uu-229388" > Immunotherapy targe...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03053naa a2200421 4500 | |
001 | oai:DiVA.org:uu-229388 | |
003 | SwePub | |
008 | 140806s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2293882 URI |
024 | 7 | a https://doi.org/10.2217/IMT.13.1622 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Lindström, Veronicau Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)veher764 |
245 | 1 0 | a Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders |
264 | 1 | c 2014 |
338 | a print2 rdacarrier | |
520 | a Immunotherapy targeting a-synuclein has evolved as a potential therapeutic strategy for neurodegenerative diseases, such as Parkinson's disease, and initial studies on cellular and animal models have shown promising results. alpha-synuclein vaccination of transgenic mice reduced the number of brain inclusions, whereas passive immunization studies demonstrated that antibodies against the C-terminus of alpha-synuclein can pass the blood-brain barrier and affect the pathology. In addition, preliminary evidence suggests that transgenic mice treated with an antibody directed against alpha-synuclein oligomers/protofibrils resulted in reduced levels of such species in the CNS. The underlying mechanisms of immunotherapy are not yet fully understood, but may include antibody-mediated clearance of pre-existing aggregates, prevention of protein propagation between cells and microglia-dependent protein clearance. Thus, immunotherapy targeting alpha-synuclein holds promise, but needs to be further developed as a future disease-modifying treatment in Parkinson's disease and other alpha-synucleinopathies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng |
653 | a alpha-synuclein | |
653 | a antibody | |
653 | a immunization | |
653 | a immunotherapy | |
653 | a Parkinson's disease | |
700 | 1 | a Ihse, Elisabetu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)elihs048 |
700 | 1 | a Fagerqvist, Thereseu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)thewa743 |
700 | 1 | a Bergström, Joakimu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)joakberg |
700 | 1 | a Nordstrom, Eva4 aut |
700 | 1 | a Moller, Christer4 aut |
700 | 1 | a Lannfelt, Larsu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)lalan021 |
700 | 1 | a Ingelsson, Martinu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)maing121 |
710 | 2 | a Uppsala universitetb Geriatrik4 org |
773 | 0 | t Immunotherapyg 6:2, s. 141-153q 6:2<141-153x 1750-743Xx 1750-7448 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-229388 |
856 | 4 8 | u https://doi.org/10.2217/IMT.13.162 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.